News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Weather
E-Edition
Subscribe
Sign Up For Newsletters
News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Oragenics, Inc.
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
April 19, 2024
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics, Inc. Files 10K and Provides Company Update
April 01, 2024
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
March 18, 2024
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
March 05, 2024
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Announces Closing of Public Offering
March 01, 2024
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Announces Pricing of Public Offering
February 27, 2024
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Announces Proposed Public Offering
February 27, 2024
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics, Inc. Announces Leadership Transition
February 12, 2024
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
February 07, 2024
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion
February 05, 2024
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Announces Termination of At-The-Market Offering Program
January 23, 2024
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
January 02, 2024
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors
October 18, 2023
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
October 05, 2023
From
Oragenics, Inc.
Via
Business Wire
Tickers
ODYY
OGEN
Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets
September 29, 2023
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics, Inc. Announces Private Placement
August 07, 2023
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM
June 05, 2023
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics to Participate in the World Vaccine Congress Washington
March 29, 2023
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE
March 14, 2023
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team
March 08, 2023
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate
March 01, 2023
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics, Inc. Regains Compliance with NYSE American
February 03, 2023
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split
December 23, 2022
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate
December 22, 2022
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics, Inc. Receives NYSE American Notice
December 20, 2022
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics, Inc. Announces New Chair
December 19, 2022
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics to Participate in the 2022 BioFlorida Annual Conference
October 24, 2022
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Issues Letter to Shareholders
September 30, 2022
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate
August 24, 2022
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer
June 23, 2022
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close